Fri, Nov 28, 2014, 2:29 PM EST - U.S. Markets closed early today


% | $
Quotes you view appear here for quick access.

Amylin Pharmaceuticals, Inc. Message Board

  • socmd2000 socmd2000 Mar 11, 2010 7:12 AM Flag

    hope for type 2 diabetics

    I am a primary care physician with many patients who have done very well with Byetta (lost weight and lowered HgbA1c) and we are all hoping that the FDA will approve EQW. I have been an investor in Amlyn for 10 years, and will remain an investor no matter which way this goes. I got in at 7 in 2000, then out at 41 in 2007, then back in at 12 in 2008. This is the real deal, nothing better for Type 2 diabetes, and it will eventually be recognized, if not tomorrow.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thanks Doc! and again, I did not mean anything by the question, I was just curious how one wrestles the "potential" conflict of interest, not that there is one here. I hope you have your LAR hat and Tshirt printed and ready to wear at the next medical conference you attend!

    • why does he personally own stock in that drugmaker? Its just a question.

      • 1 Reply to d.byrne1
      • If I believed that this was the best medicine for this diagnosis and there was no evidence that this medicine was harmful, and it was later discovered to be harmful and I did not discontinue the medicine; then I would be liable. I am happy to have been investing in Biotech for many years, and I can use my medical knowledge to evaluate the potential for these small start-ups. I do not invest in major pharmaceuticals as I find them boring and not particularly profitable.

    • I am just curious and I am not trying to imply anything but if a doctor recommended a drug and he had a personal investment in that drug company, and a patient were to get say a cancer that the drug warned could be of risk, would that in any way expose you to be in violation of any conditions of your malpractice insurance?


Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.